Effect of Treatment with Mucoactive Drugs on COPD Exacerbations During 5 years of Follow-up in the Czech Republic: A Real-World Study
Mucoactive treatment for two years reduced the number of COPD exacerbations (all, moderate) over five years of follow-up. The reduction in exacerbations was more pronounced in patients with cough or with stage 3‒4 COPD but was independent of the use of ICS.
Authors
- Michal Kopecký (ORCID: https://orcid.org/0000-0002-1191-2967)
- Jaromír Zatloukal (ORCID: https://orcid.org/0000-0002-3207-6355)
- Michal Svoboda (ORCID: https://orcid.org/0000-0003-0312-2524)
- Marek Plutinský (ORCID: https://orcid.org/0000-0003-1723-3794)
- Vladimír Koblížek (ORCID: https://orcid.org/0000-0002-2446-2790)
- Kristián Brat (ORCID: https://orcid.org/0000-0003-1674-228X)
- Clive Page (ORCID: https://orcid.org/0000-0002-9358-3799)
- Eva Voláková (ORCID: https://orcid.org/0000-0002-6388-8022)
Institutions
- King's College London (GB)
- Charles University (CZ)
- Masaryk University (CZ)
- University Hospital Olomouc (CZ)
- University Hospital Hradec Králové (CZ)
- Palacký University Olomouc (CZ)
Publication Details
- Journal
- Lung
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1007/s00408-025-00813-7
- Citations
- 1
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Univerzita Karlova v Praze
- CSL Behring
- Ministerstvo Zdravotnictví Ceské Republiky